Omega Diagnostics has announced plans to raise up to £7.25m in a share issue to help the sale of its HIV testing business.
The testing business, which is moving out of its Alva base, hopes to use the part of the money raised to initially fund the CD4 HIV testing business before it is sold to provide additional working capital.
It has so far raised £2m via a placing of just under 50 million shares at 4 pence each, with 90 million warrants for institutional investors at the same price.
